Cytoreductive surgery and hyperthermal intraperitoneal chemoperfusion in colorectal cancer and cancer of ovaries: our experience and perspectives of a new method
Objective. Studying of results of the cytoreductive operations and hyperthermal intraperitoneal chemoperfusion application for treatment of canceromatosis in colorectal cancer and ovarian cancer.
Materials and methods. In 10 patients, suffering colorectal cancer (6 men and 4 women) were performed peritonectomy, diathermo-ablation of implants, made from visceral peritoneum. Average value of the peritoneal canceromatosis index have constituted 18 (14 - 21). In 11 patients, suffering ovarian cancer, panhisterectomy, peritonectomy, omentectomy, and ablation of the visceral peritoneum implants was conducted. Median value of the peritoneal canceromatosis index was 16 (12 - 20). For hyperthermal intraperitoneal chemoperfusion oxaliplatin was used.
Results. Complete and optimal cytoreduction (degree CC0-CC1 in accordance to classification of P. H. Sugarbaker) was achieved in 5 patients, while suboptimal one (degree CC2) - in 10, and nonoptimal (degree CC3) cytoreduction - in 6 patients. Intraoperative complications were absent. Postoperative complications have occurred in 5 (23.8%) patients: the wound infection, persisting ileus, episode of partial ileus. Of 10 patients, suffering colorectal cancer, 5 died in 9-12 mo. One-year barrier have had survived 45.5% patients. Of 11 women-patients, suffering ovarian cancer, 7 died in 6-24 mo. One-year barrier have had survived 36.4% women-patients.
Conclusion. In patients, suffering colorectal cancer, the survival median was 12 mo, while in the women-patients, suffering ovarian cancer - 18 mo. Cytoreductive operations and hyperthermal intraperitoneal chemoperfusion constitute perspective method for the survival enhancement in patients, suffering canceromatosis, but only if their selection was organized.
Flood M, Narasimhan V, Waters P, Ramsay R, Michael M, Warrier S, et al. Survival after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases: A systematic review and discussion of latest controversies. Surgeon. 2020 Oct 3:S1479-666X(20)30141-4. doi: 10.1016/j.surge.2020.08.016. Epub ahead of print. PMID: 33023847.
Quenet F, Elias D, Roca L, Goere D, Ghouti L, Pocard M, et al. A UNICANCER phase III trial of hyperthermic intra-peritoneal chemotherapy (HIPEC) for colorectal peritoneal carcinomatosis (PC): PRODIGE 7. J Clin Oncol 2018;36: 18_suppl, LBA3503-LBA3503. DOI: 10.1200/JCO.2018.36.18_suppl.LBA3503
van Driel WJ, Koole SN, Sikorska K, Schagen van Leeuwen JH, Schreuder HWR, Hermans RHM, et al. Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer. N Engl J Med. 2018 Jan 18;378(3):230-40. doi: 10.1056/NEJMoa1708618. PMID: 29342393.
Kim SI, Cho J, Lee EJ, Park S, Park SJ, Seol A, et al. Selection of patients with ovarian cancer who may show survival benefit from hyperthermic intraperitoneal chemotherapy: A systematic review and meta-analysis. Medicine (Baltimore). 2019 Dec;98(50):e18355. doi: 10.1097/MD.0000000000018355. PMID: 31852138; PMCID: PMC6922570.
Zhao PY, Hu SD, Li YX, Yao RQ, Ren C, He CZ, et al. Clinical Efficacy and Safety of Hyperthermic Intraperitoneal Chemotherapy in Colorectal Cancer Patients at High Risk of Peritoneal Carcinomatosis: A Systematic Review and Meta-Analysis. Front Surg. 2020 Nov 17;7:590452. doi: 10.3389/fsurg.2020.590452. PMID: 33282908; PMCID: PMC7705102.
Verwaal VJ, Bruin S, Boot H, van Slooten G, van Tinteren H. 8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. Ann Surg Oncol. 2008 Sep;15(9):2426-32. doi: 10.1245/s10434-008-9966-2. Epub 2008 Jun 3. PMID: 18521686.
van Eden WJ, Kok NFM, Woensdregt K, Huitema ADR, Boot H, Aalbers AGJ. Safety of intraperitoneal Mitomycin C versus intraperitoneal oxaliplatin in patients with peritoneal carcinomatosis of colorectal cancer undergoing cytoreductive surgery and HIPEC. Eur J Surg Oncol. 2018 Feb;44(2):220-7. doi: 10.1016/j.ejso.2017.10.216. Epub 2017 Nov 15. PMID: 29258720.
Zhang X, Wu Q, Wei M, Deng X, Gu C, Wang Z. Oxaliplatin versus mitomycin C in HIPEC for peritoneal metastasis from colorectal cancer: a systematic review and meta-analysis of comparative studies. Int J Colorectal Dis. 2020 Oct;35(10):1831-9. doi: 10.1007/s00384-020-03702-y. Epub 2020 Jul 28. PMID: 32725345.
Kitai T. The role of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the treatment of peritoneal carcinomatosis: a systematic review including evidence from Japan. Surg Today. 2020 Nov 13. doi: 10.1007/s00595-020-02180-7. Epub ahead of print. PMID: 33185798.
Auer RC, Sivajohanathan D, Biagi J, Conner J, Kennedy E, May T. Indications for hyperthermic intraperitoneal chemotherapy with cytoreductive surgery: a systematic review. Eur J Cancer. 2020 Mar;127:76-95. doi: 10.1016/j.ejca.2019.10.034. Epub 2020 Jan 24. PMID: 31986452.
Helm JH, Miura JT, Glenn JA, Marcus RK, Larrieux G, Jayakrishnan TT, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: a systematic review and meta-analysis. Ann Surg Oncol. 2015 May;22(5):1686-93. doi: 10.1245/s10434-014-3978-x. Epub 2014 Aug 15. PMID: 25124472.
Cai Z, Cai Z, He T, Zhao Z, Yin Y, Shen C, et al. Comparative effectiveness of hyperthermic intraperitoneal chemotherapy for gastric cancer: A systematic review and network meta-analysis protocol. Medicine (Baltimore). 2018 Aug;97(33):e11949. doi: 10.1097/MD.0000000000011949. Erratum in: Medicine (Baltimore). 2019 Feb;98(6):e14487. PMID: 30113499; PMCID: PMC6112913.
Desiderio J, Chao J, Melstrom L, Warner S, Tozzi F, Fong Y, Parisi A, Woo Y. The 30-year experience-A meta-analysis of randomised and high-quality non-randomised studies of hyperthermic intraperitoneal chemotherapy in the treatment of gastric cancer. Eur J Cancer. 2017 Jul;79:1-14. doi: 10.1016/j.ejca.2017.03.030. Epub 2017 Apr 26. PMID: 28456089; PMCID: PMC5568419.
Hallam S, Tyler R, Price M, Beggs A, Youssef H. Meta-analysis of prognostic factors for patients with colorectal peritoneal metastasis undergoing cytoreductive surgery and heated intraperitoneal chemotherapy. BJS Open. 2019 Jun 27;3(5):585-94. doi: 10.1002/bjs5.50179. PMID: 31592510; PMCID: PMC6773657.
Hulshof EC, Lim L, de Hingh IHJT, Gelderblom H, Guchelaar HJ, Deenen MJ. Genetic Variants in DNA Repair Pathways as Potential Biomarkers in Predicting Treatment Outcome of Intraperitoneal Chemotherapy in Patients With Colorectal Peritoneal Metastasis: A Systematic Review. Front Pharmacol. 2020 Oct 6;11:577968. doi: 10.3389/fphar.2020.577968. PMID: 33117169; PMCID: PMC7575928.
Hernot S, van Manen L, Debie P, Mieog JSD, Vahrmeijer AL. Latest developments in molecular tracers for fluorescence image-guided cancer surgery. Lancet Oncol. 2019 Jul;20(7):e354-e367. doi: 10.1016/S1470-2045(19)30317-1. PMID: 31267970.
Schaap DP, de Valk KS, Deken MM, Meijer RPJ, Burggraaf J, Vahrmeijer AL, Kusters M; SGM-101 study group. Carcinoembryonic antigen-specific, fluorescent image-guided cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for metastatic colorectal cancer. Br J Surg. 2020 Mar;107(4):334-7. doi: 10.1002/bjs.11523. Epub 2020 Jan 21. PMID: 31960953; PMCID: PMC7079046.
Vuijk FA, Hilling DE, Mieog JSD, Vahrmeijer AL. Fluorescent-guided surgery for sentinel lymph node detection in gastric cancer and carcinoembryonic antigen targeted fluorescent-guided surgery in colorectal and pancreatic cancer. J Surg Oncol. 2018 Aug;118(2):315-23. doi: 10.1002/jso.25139. Epub 2018 Sep 14. PMID: 30216455; PMCID: PMC6175076.
National Comprehensive Cancer Network [Internet]. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Colon Cancer (Version 1.2021). [Accessed 2020 December 22]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf
National Comprehensive Cancer Network [Internet]. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Ovarian Cancer Including Fallopian Tube Cancer and Primary Peritoneal Cancer (Version 1.2020). [Accessed 2020 March 11]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/ovarian.pdf/
This work is licensed under a Creative Commons Attribution 4.0 International License.